US › Healthcare

Neuropace Inc (NPCE)

US · Healthcare · Medical Devices

$14.14+4.74%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$22.1M
Revenue YoY
-2.0%
Net profit
$-6.7M
Profit YoY
-1.5%
EPS
$-0.20
EPS estimate
$-0.23
Net margin
-30.3%

EPS came in at -0.20 against a street estimate of -0.23 — a beat of 13.6%.

Key statistics

Market cap
$439.5M
Forward P/E
0.0
P/B
30.38
Book value
$0.43
EPS (TTM)
$-0.65
52-week high
$19.60
52-week low
$7.56
50-day MA
$15.93
200-day MA
$15.09
Beta
1.89

Analyst view

Analysts rate Neuropace Inc a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $20.22.

Shareholding

Insiders
4.04%
Institutions
96.28%

Largest institutional holders

FundStake
Polar Capital Holdings PLC9.67%
Soleus Capital Management, L.P.8.60%
Morgan Stanley - Brokerage Accounts7.53%
First Light Asset Management, LLC7.22%
BlackRock Inc6.88%
Orbimed Advisors, LLC6.15%
Driehaus Capital Management LLC4.26%
Vanguard Capital Management, LLC3.30%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Neuropace Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.